Tech Company M&A Transactions
Amplimmune Acquisition
Amplimmune was acquired by MedImmune. The transaction occurred on 10/8/2013. MedImmune said the transaction price was $500 million.
Transaction Overview
Company Name
Acquired By
Announced On
10/8/2013
Transaction Type
M&A
Amount
$500,000,000
M&A Terms
MedImmune will pay an initial consideration of $225m and deferred consideration of up to $275m based on predetermined development milestones being hit.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
45 W Watkins Mill Rd Suite A
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Website
Email Address
Not Recorded
Overview
Founded in 2007 and headquartered in Gaithersburg, MD, Amplimmune is focused on developing novel co-stimulatory/co-inhibitory molecules that rebalance the immune system and are intended for treating cancer, autoimmune disease, infectious disease, and transplantation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Richman
Browse more venture capital transactions:
Prev: 10/8/2013: BASIS Science venture capital transaction
Next: 10/8/2013: Ingo Money venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. All VC database entries reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs